Skip to content

Metabonomics study on the treatment of sepsis by Supplemented Xijiao Dihuang Tang

Metabonomics study on the treatment of sepsis by Supplemented Xijiao Dihuang Tang

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2023000015
Enrollment
Unknown
Registered
2023-06-02
Start date
2023-06-02
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Supplemented Xijiao Dihuang Tang combined with conventional Western medicine treatment group:Oral or nasal feeding Supplemented Xijiao Dihuang Tang combined with conventional Western medicine treatme
(2) Use dynamic monitoring to guide fluid resuscitation, such as stroke volume (SV), stroke volume variation (SVV), pulse pressure variation (PPV), and echocardiography
(3) The use of antibiotics: for suspected septic shock or sepsis patients, anti-infection therapy should be carried out immediately within 1 hour of definite diagnosis
(4) Use of vasoactive agents: norepinephrine is the first choice for patients with septic shock. The mean arterial pressure (MAP) level after norepinephrine was still not up to the standard, and vasop

Sponsors

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Meet the Berlin criteria for Sepsis 3.0; 2) Traditional Chinese Medicine clinical syndrome differentiation was syndrome of heat entering nutrient-blood aspects, and the syndrome type was determined by 2 intermediate professional titles or above; 3) Age =18 years old, gender unlimited; 4) Good compliance, follow-up, voluntary participation in the study, and informed consent signed by oneself or their family members.

Exclusion criteria

Exclusion criteria: 1) Those who do not meet the inclusion criteria; 2) Under the age of 18; 3) lactating and pregnant women; 4) Complicated with serious primary diseases of heart, brain, liver and kidney; 5) Allergic constitution or allergic to the drugs in this study; 6) Mental or cognitive impairment, poor compliance, unable to cooperate with the researcher; 7) Participating in other clinical studies at the same time may affect the observers of effect indicators of this study.

Design outcomes

Primary

MeasureTime frame
Length of stay in intensive care unit;metabolome(blood);28-day mortality rate;Traditional Chinese Medicine clinical symptom score;

Secondary

MeasureTime frame
hemoglobin;Acute Physiology and Chronic Health Evaluation ? score;Hypersensitive C-reactive protein;Sequential Organ Failure Assessment score;White blood cell count;Modified Marshall score;Platelet count;

Countries

China

Contacts

Public ContactZhijun Fang

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine

1248256089@qq.com13372018676

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026